TD Cowen started coverage on shares of Allurion Technologies (NYSE:ALUR – Free Report) in a research report released on Wednesday, MarketBeat Ratings reports. The firm issued a buy rating and a $2.00 target price on the stock.
Other equities research analysts have also recently issued reports about the company. Roth Mkm assumed coverage on Allurion Technologies in a research note on Friday, September 6th. They issued a buy rating and a $2.00 price objective for the company. Roth Capital raised Allurion Technologies to a strong-buy rating in a research report on Friday, September 6th. Finally, Chardan Capital reduced their price target on shares of Allurion Technologies from $5.00 to $2.50 and set a buy rating on the stock in a research report on Thursday, August 22nd. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of Buy and an average target price of $2.88.
Get Our Latest Research Report on Allurion Technologies
Allurion Technologies Price Performance
Allurion Technologies (NYSE:ALUR – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported $0.01 EPS for the quarter. The company had revenue of $11.77 million during the quarter. Sell-side analysts anticipate that Allurion Technologies will post -0.3 EPS for the current fiscal year.
Hedge Funds Weigh In On Allurion Technologies
An institutional investor recently bought a new position in Allurion Technologies stock. CVI Holdings LLC purchased a new position in shares of Allurion Technologies Inc. (NYSE:ALUR – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 521,440 shares of the company’s stock, valued at approximately $520,000. Allurion Technologies makes up 0.5% of CVI Holdings LLC’s portfolio, making the stock its 28th largest position. CVI Holdings LLC owned about 1.09% of Allurion Technologies as of its most recent SEC filing. Institutional investors own 21.39% of the company’s stock.
About Allurion Technologies
Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.
Featured Articles
- Five stocks we like better than Allurion Technologies
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- How to invest in marijuana stocks in 7 steps
- MarketBeat Week in Review – 9/30 – 10/4
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Allurion Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allurion Technologies and related companies with MarketBeat.com's FREE daily email newsletter.